Oscar Clinical Guideline: Veozah (fezolinetant) (PG215, Ver. 1)

Veozah (fezolinetant)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Vasomotor symptoms (VMS), including hot flashes and night sweats, are common symptoms of menopause that can significantly impact quality of life. They are caused by the decline in estrogen levels during the menopausal transition. Hormone therapy (HT) with estrogen, with or without progestogens, is the most effective treatment for VMS. However, HT may not be appropriate for all women, such as those with a history of breast cancer, cardiovascular disease, or venous thromboembolism. Nonhormonal treatment options for VMS include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other medications like gabapentin. Veozah (fezolinetant) is an once-daily oral neurokinin-3 receptor antagonist approved for the treatment of moderate to severe VMS associated with menopause. It provides an additional nonhormonal treatment option for women who cannot or choose not to use HT.

Definitions

"**Menopause**" refers to the point in time 12 months after a woman's last menstrual period, marking the end of the menopausal transition.

"**Perimenopause**" is the menopausal transition, a span of time starting when a woman begins experiencing menstrual irregularity through 12 months after the final menstrual period.

"**Postmenopause**" refers to the time after menopause has occurred, starting 12 months after the final menstrual period.

"**Vasomotor symptoms (VMS)**" refer to hot flashes (sensations of heat, sweating, flushing) and night sweats associated with the menopausal transition.

Medical Necessity Criteria for Initial Authorization

The Plan considers **Veozah (fezolinetant)** medically necessary when **ALL** of the following criteria are met:

1. The member is a postmenopausal woman with moderate to severe vasomotor symptoms (VMS); ***AND***
2. The member is unable to use, or has tried and failed an 8-week trial of **BOTH** of the following:
    a. Hormonal pharmacologic treatments (i.e., estrogen, with progestin if uterus present), such as **ANY** of the following:
        i. Oral estrogens - e.g., estradiol, conjugated estrogens (Cenestin, Enjuvia, Premarin), esterified estrogens (Menest); ***or***
        ii. Transdermal estrogens - e.g., estradiol patch (Alora, Climara, Estraderm, VivelleDot, Minivelle); ***or***
        iii. Topical Products - e.g., estradiol gel (Divigel, Elestrin, EstroGel), estradiol emulsion (Estrasorb), estradiol transdermal spray (Evamist); ***or***
        iv. Oral estrogen/progestin combinations - e.g., Prempro (conjugated estrogens/medroxyprogesterone), Activella (estradiol/norethindrone), Angeliq (estradiol/drospirenone), Bijuva (estradiol/progesterone); ***or***
        v. Transdermal estrogen/progestin combinations - e.g., CombiPatch (estradiol/norethindrone), Climara Pro (estradiol/levonorgestrel); ***and***
    b. Nonhormonal pharmacologic treatments, such as **ANY** of the following:
        i. SSRIs (selective serotonin reuptake inhibitors) - e.g., paroxetine (Paxil, Brisdelle), citalopram (Celexa), escitalopram (Lexapro); ***or***

ii. SNRIs (serotonin norepinephrine reuptake inhibitors) - e.g., venlafaxine (Effexor), desvenlafaxine (Pristiq); ***or***

iii. Gabapentin; ***AND***

3. The members does not have cirrhosis, severe renal impairment, or end-stage renal disease; ***AND***
4. The requested medication is being used within the Plan's Quantity Limit of 1 tablet daily.

If the above prior authorization criteria are met, the requested product will be authorized for 6-months.

Medical Necessity Criteria for Reauthorization

Reauthorization for continued coverage of Veozah (fezolinetant) for an additional 12 months may be granted if the member has recent (within the last 3 months) clinical chart documentation indicating **ALL** of the following criteria:

1. The member continues to experience moderate to severe vasomotor symptoms (VMS, or hot flashes) that warrant ongoing treatment; ***AND***
2. Clinically significant reduction in the frequency and/or severity of VMS from baseline, such as:
    a. Reduction in the frequency of moderate to severe hot flashes; ***or***
    b. Reduction in the severity of hot flashes from severe to moderate, moderate to mild, or complete resolution; ***or***
    c. Improvement in VMS-related quality of life, sleep, or other member-reported outcomes; ***AND***
3. The member has not developed any new contraindications to continued therapy with fezolinetant, such as:
    a. Cirrhosis; ***or***
    b. Severe renal impairment or end-stage renal disease; ***or***
    c. Initiation of a strong or moderate CYP1A2 inhibitor.

Experimental or Investigational / Not Medically Necessary

Veozah (fezolinetant) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Use in perimenopausal women (before menopause has been reached), as efficacy and safety have not been established in this population.

- Use for treatment of mild VMS, as pivotal trials only included women with moderate to severe VMS defined as ≥7 moderate to severe hot flashes per day or ≥50 per week.
- Use for non-menopausal VMS associated with breast cancer treatment, prostate cancer treatment, or other causes, as efficacy and safety for these indications are unknown.

Appendix

Table 1 - Contraindications to hormone therapy

Absolute contraindications	Relative contraindications
I. Acute cardiovascular disease II. Acute or decompensated liver disease III. History of breast cancer IV. History of cardiovascular disease (coronary artery disease or stroke) V. History of endometrial cancer VI. History of venous thromboembolism VII. Hypertriglyceridemia VIII. Pregnancy IX. Prolonged immobilization X. Unexplained vaginal bleeding	XI. Active gallbladder disease XII. Increased risk of breast cancer XIII. Increased risk of cardiovascular disease XIV. Migraine with aura

References

1. "The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun 1;30(6):573-590. doi: 10.1097/GME.0000000000002200. PMID: 37252752.
2. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. PMID: 35797481.
3. Arinkan, S.A. and Gunacti, M. (2021), Factors influencing age at natural menopause. J. Obstet. Gynaecol. Res., 47: 913-920. https://doi.org/10.1111/jog.14614
4. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS. Erratum in: Endocr Pract. 2017 Dec;23 (12):1488. PMID: 28703650.
5. Drugs for Menopausal Symptoms. JAMA. 2021;325(23):2394–2395. doi:10.1001/jama.2020.15592

6. Flores VA, Pal L, Manson JE. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Endocr Rev. 2021 Nov 16;42(6):720-752. doi: 10.1210/endrev/bnab011. PMID: 33858012.
7. Langer, R. D., Hodis, H. N., Lobo, R. A., & Allison, M. A. (2021). Hormone replacement therapy – where are we now? Climacteric, 24(1), 3–10. https://doi.org/10.1080/13697137.2020.1851183
8. Melissa A. McNeil, Sarah B. Merriam. Menopause. Ann Intern Med.2021;174:ITC97-ITC112. [Epub 13 July 2021]. doi:10.7326/AITC202107200
9. Salvatore, S., Benini, V., Ruffolo, A. F., Degliuomini, R. S., Redaelli, A., Casiraghi, A., & Candiani, M. (2023). Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert Opinion on Pharmacotherapy, 24(1), 23–28. https://doi.org/10.1080/14656566.2022.2152326
10. US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740–1746. doi:10.1001/jama.2022.18625
11. Veozah (fezolinetant) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; May 2023.

Clinical Guideline Revision / History Information

Original Date: 06/27/2024
Reviewed/Revised: